{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:04:40Z","timestamp":1784174680489,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,15]]},"DOI":"10.7759\/cureus.112751","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T03:35:31Z","timestamp":1784172931000},"source":"Crossref","is-referenced-by-count":0,"title":["Antithrombotic Drug Eruptions in Dermatology Practice: Selection Bias, Clinical Phenotypes, and Diagnostic Approaches"],"prefix":"10.7759","author":[{"given":"Tomoaki","family":"Takada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(05)80029-0","article-title":"Side-effects of antithrombotic therapy","volume":"3","author":"Levine MN","year":"1990","unstructured":"Levine MN, Anderson DR. Side-effects of antithrombotic therapy. Baillieres Clin Haematol. 1990, 3:815-29. 10.1016\/S0950-3536(05)80029-0","journal-title":"Baillieres Clin Haematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.10.027","article-title":"A review of traditional and novel oral anticoagulant and antiplatelet therapy for dermatologists and dermatologic surgeons","volume":"72","author":"Brown DG","year":"2015","unstructured":"Brown DG, Wilkerson EC, Love WE. A review of traditional and novel oral anticoagulant and antiplatelet therapy for dermatologists and dermatologic surgeons. J Am Acad Dermatol. 2015, 72:524-34. 10.1016\/j.jaad.2014.10.027","journal-title":"J Am Acad Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/1203475417716364","article-title":"Adverse drug reactions and cutaneous manifestations associated with anticoagulation","volume":"21","author":"Vu TT","year":"2017","unstructured":"Vu TT, Gooderham M. Adverse drug reactions and cutaneous manifestations associated with anticoagulation. J Cutan Med Surg. 2017, 21:540-50. 10.1177\/1203475417716364","journal-title":"J Cutan Med Surg"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2020.06.015","article-title":"Drug-induced cutaneous vasculitis and anticoagulant-related cutaneous adverse reactions: insights in pathogenesis, clinical presentation, and treatment","volume":"38","author":"Guzman AK","year":"2020","unstructured":"Guzman AK, Balagula Y. Drug-induced cutaneous vasculitis and anticoagulant-related cutaneous adverse reactions: insights in pathogenesis, clinical presentation, and treatment. Clin Dermatol. 2020, 38:613-28. 10.1016\/j.clindermatol.2020.06.015","journal-title":"Clin Dermatol"},{"key":"ref5","doi-asserted-by":"crossref","DOI":"10.1001\/archderm.1968.01610140034006","article-title":"Cutaneous reactions to anticoagulants","volume":"98","author":"Schiff BL","year":"1968","unstructured":"Schiff BL, Kern AB. Cutaneous reactions to anticoagulants. Arch Dermatol. 1968, 98:136-7.","journal-title":"Arch Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2006.01227.x","article-title":"Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options","volume":"61","author":"Bircher AJ","year":"2006","unstructured":"Bircher AJ, Harr T, Hohenstein L, Tsakiris DA. Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options. Allergy. 2006, 61:1432-40. 10.1111\/j.1398-9995.2006.01227.x","journal-title":"Allergy"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60409-7","article-title":"Heparin-induced skin lesions","volume":"380","author":"Schindewolf M","year":"2012","unstructured":"Schindewolf M, Lindhoff-Last E, Ludwig RJ, Boehncke WH. Heparin-induced skin lesions. Lancet. 2012, 380:1867-79. 10.1016\/S0140-6736(12)60409-7","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.23822\/EurAnnACI.1764-1489.80","article-title":"Hypersensitivity reactions to non-vitamin K oral anticoagulants: a review of literature and diagnostic work-up proposal","volume":"51","author":"Carli G","year":"2019","unstructured":"Carli G, Farsi A, Chiarini F, Lippolis D, Cortellini G. Hypersensitivity reactions to non-vitamin K oral anticoagulants: a review of literature and diagnostic work-up proposal. Eur Ann Allergy Clin Immunol. 2019, 51:7-14. 10.23822\/EurAnnACI.1764-1489.80","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.23822\/EurAnnACI.1764-1489.71","article-title":"Delayed hypersensitivity to new oral anticoagulants: demonstration of cross-reactivity for the drug category and definition of non-irritant concentrations for patch tests","volume":"51","author":"Cortellini G","year":"2019","unstructured":"Cortellini G, Rossi F, Lippolis D, Cortellini F, Gavioli B, Ballardini G. Delayed hypersensitivity to new oral anticoagulants: demonstration of cross-reactivity for the drug category and definition of non-irritant concentrations for patch tests. Eur Ann Allergy Clin Immunol. 2019, 51:38-40. 10.23822\/EurAnnACI.1764-1489.71","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-0546(03)79206-4","article-title":"Allergy to heparin: a new in vitro diagnostic technique","volume":"31","author":"Caballero MR","year":"2003","unstructured":"Caballero MR, Fernandez-Benitez M. Allergy to heparin: a new in vitro diagnostic technique. Allergol Immunopathol (Madr). 2003, 31:324-8. 10.1016\/S0301-0546(03)79206-4","journal-title":"Allergol Immunopathol (Madr)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2004.01891.x","article-title":"In vitro allergy diagnosis: should we follow the flow?","volume":"34","author":"Ebo DG","year":"2004","unstructured":"Ebo DG, Hagendorens MM, Bridts CH, Schuerwegh AJ, De Clerck LS, Stevens WJ. In vitro allergy diagnosis: should we follow the flow?. Clin Exp Allergy. 2004, 34:332-9. 10.1111\/j.1365-2222.2004.01891.x","journal-title":"Clin Exp Allergy"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.15036\/arerugi.75.163","article-title":"Key points for drug eruptions in daily practice (Article in Japan)","volume":"75","author":"Watanabe Y","year":"2026","unstructured":"Watanabe Y. Key points for drug eruptions in daily practice (Article in Japan). Arerugi. 2026, 75:163-70. 10.15036\/arerugi.75.163","journal-title":"Arerugi"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2025.100625","article-title":"Evaluation of drug-induced lymphocyte stimulation test in mesalazine-associated allergic drug reaction","volume":"5","author":"Fukasawa N","year":"2026","unstructured":"Fukasawa N, Kiyohara H, Adachi T, et al.. Evaluation of drug-induced lymphocyte stimulation test in mesalazine-associated allergic drug reaction. J Allergy Clin Immunol Glob. 2026, 5:100625. 10.1016\/j.jacig.2025.100625","journal-title":"J Allergy Clin Immunol Glob"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2019.03.006","article-title":"Drug-induced hypersensitivity syndrome (DiHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): an update in 2019","volume":"68","author":"Shiohara T","year":"2019","unstructured":"Shiohara T, Mizukawa Y. Drug-induced hypersensitivity syndrome (DiHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): an update in 2019. Allergol Int. 2019, 68:301-8. 10.1016\/j.alit.2019.03.006","journal-title":"Allergol Int"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.IJD_582_17","article-title":"Drug reaction with eosinophilia and systemic symptoms: an update and review of recent literature","volume":"63","author":"De A","year":"2018","unstructured":"De A, Rajagopalan M, Sarda A, Das S, Biswas P. Drug reaction with eosinophilia and systemic symptoms: an update and review of recent literature. Indian J Dermatol. 2018, 63:30-40. 10.4103\/ijd.IJD_582_17","journal-title":"Indian J Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10050999","article-title":"Drug reaction with eosinophilia and systemic symptoms (DReSS)\/drug-induced hypersensitivity syndrome (DIHS) - readdressing the DReSS","volume":"10","author":"Stirton H","year":"2022","unstructured":"Stirton H, Shear NH, Dodiuk-Gad RP. Drug reaction with eosinophilia and systemic symptoms (DReSS)\/drug-induced hypersensitivity syndrome (DIHS) - readdressing the DReSS. Biomedicines. 2022, 10:999. 10.3390\/biomedicines10050999","journal-title":"Biomedicines"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22042147","article-title":"Current perspective regarding the immunopathogenesis of drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms (DIHS\/DRESS)","volume":"22","author":"Miyagawa F","year":"2021","unstructured":"Miyagawa F, Asada H. Current perspective regarding the immunopathogenesis of drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms (DIHS\/DRESS). Int J Mol Sci. 2021, 22:2147. 10.3390\/ijms22042147","journal-title":"Int J Mol Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.70136","article-title":"Guidelines for the management of Stevens-Johnson syndrome and toxic epidermal necrolysis 2025 supplement","volume":"53","author":"Watanabe H","year":"2026","unstructured":"Watanabe H, Ogawa Y, Yamaguchi Y, et al.. Guidelines for the management of Stevens-Johnson syndrome and toxic epidermal necrolysis 2025 supplement. J Dermatol. 2026, 53:e88-e101. 10.1111\/1346-8138.70136","journal-title":"J Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2025.05.008","article-title":"Recent advances in the diagnosis and treatment of Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"74","author":"Watanabe Y","year":"2025","unstructured":"Watanabe Y, Hama N. Recent advances in the diagnosis and treatment of Stevens-Johnson syndrome\/toxic epidermal necrolysis. Allergol Int. 2025, 74:345-55. 10.1016\/j.alit.2025.05.008","journal-title":"Allergol Int"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1096-8652(199803)57:3<233::aid-ajh10>3.0.co;2-b","article-title":"Late-onset warfarin-induced skin necrosis: case report and review of the literature","volume":"57","author":"Essex DW","year":"1998","unstructured":"Essex DW, Wynn SS, Jin DK. Late-onset warfarin-induced skin necrosis: case report and review of the literature. Am J Hematol. 1998, 57:233-7. 10.1002\/(sici)1096-8652(199803)57:3&lt;233::aid-ajh10&gt;3.0.co;2-b","journal-title":"Am J Hematol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-218015","article-title":"A case of warfarin-induced skin necrosis in the setting of protein C deficiency","volume":"2017","author":"Lai J","year":"2017","unstructured":"Lai J, Ramai D, Alchi R, Bloomfield D. A case of warfarin-induced skin necrosis in the setting of protein C deficiency. BMJ Case Rep. 2017, 2017:218015. 10.1136\/bcr-2016-218015","journal-title":"BMJ Case Rep"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v7.i24.4285","article-title":"Successful treatment of warfarin-induced skin necrosis using oral rivaroxaban: a case report","volume":"7","author":"Kamada M","year":"2019","unstructured":"Kamada M, Kenzaka T. Successful treatment of warfarin-induced skin necrosis using oral rivaroxaban: a case report. World J Clin Cases. 2019, 7:4285-91. 10.12998\/wjcc.v7.i24.4285","journal-title":"World J Clin Cases"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20187310","article-title":"Warfarin-induced skin necrosis in a patient with protein S deficiency","volume":"93","author":"Fraga R","year":"2018","unstructured":"Fraga R, Diniz LM, Lucas EA, Emerich PS. Warfarin-induced skin necrosis in a patient with protein S deficiency. An Bras Dermatol. 2018, 93:612-3. 10.1590\/abd1806-4841.20187310","journal-title":"An Bras Dermatol"},{"key":"ref24","doi-asserted-by":"crossref","DOI":"10.1001\/archderm.1983.01650290040014","article-title":"Heparin-induced cutaneous necrosis unrelated to injection sites. A sign of potentially lethal complications","volume":"119","author":"Levine LE","year":"1983","unstructured":"Levine LE, Bernstein JE, Soltani K, Medenica MM, Yung CW. Heparin-induced cutaneous necrosis unrelated to injection sites. A sign of potentially lethal complications. Arch Dermatol. 1983, 119:400-3.","journal-title":"Arch Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1177\/1753495X261445510","article-title":"Delayed-type hypersensitivity to low-molecular-weight heparin and cross-reactivity to fondaparinux and danaparoid in a twin pregnancy","volume":"2026","author":"House E","year":"2026","unstructured":"House E, Pastore G, Wilson C, Morton A. Delayed-type hypersensitivity to low-molecular-weight heparin and cross-reactivity to fondaparinux and danaparoid in a twin pregnancy. Obstet Med. 2026, 2026:5510. 10.1177\/1753495X261445510","journal-title":"Obstet Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1177\/1753495X221102709","article-title":"Cutaneous hypersensitivity reaction to low molecular weight heparins in pregnancy, cross reactivity and prednisolone treatment: a case report","volume":"16","author":"Saraiva S","year":"2023","unstructured":"Saraiva S, Martins M, Sereno S, Ferreira P, Pinto A, Rasteiro C. Cutaneous hypersensitivity reaction to low molecular weight heparins in pregnancy, cross reactivity and prednisolone treatment: a case report. Obstet Med. 2023, 16:260-2. 10.1177\/1753495X221102709","journal-title":"Obstet Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2005.02266.x","article-title":"Lichen planus-type drug eruption resulting from ticlopidine","volume":"44","author":"Kurokawa I","year":"2005","unstructured":"Kurokawa I, Umehara M, Nishijima S. Lichen planus-type drug eruption resulting from ticlopidine. Int J Dermatol. 2005, 44:436-7. 10.1111\/j.1365-4632.2005.02266.x","journal-title":"Int J Dermatol"},{"key":"ref28","article-title":"Lyell syndrome due to ticlopidine","volume":"146","author":"Strippoli D","year":"2011","unstructured":"Strippoli D, Russo G, Simonetti V, Motolese A. Lyell syndrome due to ticlopidine. G Ital Dermatol Venereol. 2011, 146:497-500.","journal-title":"G Ital Dermatol Venereol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A081","article-title":"Multiple fixed-drug eruption and diarrhea with ticlopidine","volume":"36","author":"Borr\u00e1s-Blasco J","year":"2002","unstructured":"Borr\u00e1s-Blasco J, Navarro-Ruiz A, Guti\u00e9rrez-Casbas A, Matarredona-Catal\u00e1 J, Gonz\u00e1lez-Delgado M. Multiple fixed-drug eruption and diarrhea with ticlopidine. Ann Pharmacother. 2002, 36:344-5. 10.1345\/aph.1A081","journal-title":"Ann Pharmacother"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G587","article-title":"Rash with both clopidogrel and ticlopidine in two patients following percutaneous coronary intervention with drug-eluting stents","volume":"40","author":"Makkar K","year":"2006","unstructured":"Makkar K, Wilensky RL, Julien MB, Herrmann HC, Spinler SA. Rash with both clopidogrel and ticlopidine in two patients following percutaneous coronary intervention with drug-eluting stents. Ann Pharmacother. 2006, 40:1204-7. 10.1345\/aph.1G587","journal-title":"Ann Pharmacother"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2018.06.033","article-title":"Stevens-Johnson syndrome and treatment with clopidogrel","volume":"72","author":"B\u00e1ez-Ferrer N","year":"2019","unstructured":"B\u00e1ez-Ferrer N, Grande-Flecha AS, Dom\u00ednguez-Rodr\u00edguez A. Stevens-Johnson syndrome and treatment with clopidogrel. Rev Esp Cardiol (Engl Ed). 2019, 72:674. 10.1016\/j.rec.2018.06.033","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0366-6999.2011.03.027","article-title":"Toxic epidermal necrolysis after percutaneous coronary intervention: which drug is the culprit?","volume":"124","author":"Hou XM","year":"2011","unstructured":"Hou XM, Wu WY. Toxic epidermal necrolysis after percutaneous coronary intervention: which drug is the culprit?. Chin Med J (Engl). 2011, 124:467-8. 10.3760\/cma.j.issn.0366-6999.2011.03.027","journal-title":"Chin Med J (Engl)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1586\/ecp.10.30","article-title":"Clopidogrel hypersensitivity: clinical challenges and options for management","volume":"3","author":"Campbell KL","year":"2010","unstructured":"Campbell KL, Cohn JR, Savage MP. Clopidogrel hypersensitivity: clinical challenges and options for management. Expert Rev Clin Pharmacol. 2010, 3:553-61. 10.1586\/ecp.10.30","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2010.11.002","article-title":"Management of clopidogrel hypersensitivity without drug interruption","volume":"107","author":"Campbell KL","year":"2011","unstructured":"Campbell KL, Cohn JR, Fischman DL, Walinsky P, Mallya R, Jaffrani W, Savage MP. Management of clopidogrel hypersensitivity without drug interruption. Am J Cardiol. 2011, 107:812-6. 10.1016\/j.amjcard.2010.11.002","journal-title":"Am J Cardiol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.06.040","article-title":"Characterization of clopidogrel hypersensitivity reactions and management with oral steroids without clopidogrel discontinuation","volume":"58","author":"Cheema AN","year":"2011","unstructured":"Cheema AN, Mohammad A, Hong T, et al.. Characterization of clopidogrel hypersensitivity reactions and management with oral steroids without clopidogrel discontinuation. J Am Coll Cardiol. 2011, 58:1445-54. 10.1016\/j.jacc.2011.06.040","journal-title":"J Am Coll Cardiol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0414-x","article-title":"Management strategies for clopidogrel hypersensitivity","volume":"75","author":"Beavers CJ","year":"2015","unstructured":"Beavers CJ, Carris NW, Ruf KM. Management strategies for clopidogrel hypersensitivity. Drugs. 2015, 75:999-1007. 10.1007\/s40265-015-0414-x","journal-title":"Drugs"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.2174\/1570161116666180820123041","article-title":"Clopidogrel hypersensitivity: overview of the problem","volume":"17","author":"Savage MP","year":"2019","unstructured":"Savage MP, Fischman DL. Clopidogrel hypersensitivity: overview of the problem. Curr Vasc Pharmacol. 2019, 17:108-9. 10.2174\/1570161116666180820123041","journal-title":"Curr Vasc Pharmacol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.2174\/1570161116666181031143628","article-title":"Clopidogrel hypersensitivity: presentation and diagnosis","volume":"17","author":"Ford MK","year":"2019","unstructured":"Ford MK, Cohn JR. Clopidogrel hypersensitivity: presentation and diagnosis. Curr Vasc Pharmacol. 2019, 17:110-2. 10.2174\/1570161116666181031143628","journal-title":"Curr Vasc Pharmacol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.2174\/1570161116666180730100346","article-title":"Treatment of clopidogrel hypersensitivity: the Jefferson approach","volume":"17","author":"Vishnevsky A","year":"2019","unstructured":"Vishnevsky A, Savage MP, Fischman DL, et al.. Treatment of clopidogrel hypersensitivity: the Jefferson approach. Curr Vasc Pharmacol. 2019, 17:123-6. 10.2174\/1570161116666180730100346","journal-title":"Curr Vasc Pharmacol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1695177","article-title":"Clopidogrel-induced drug-induced hypersensitivity syndrome following percutaneous coronary intervention: a case report of therapeutic dilemma and management strategy","volume":"16","author":"Wang S","year":"2025","unstructured":"Wang S, Zhou J, Sun Y. Clopidogrel-induced drug-induced hypersensitivity syndrome following percutaneous coronary intervention: a case report of therapeutic dilemma and management strategy. Front Pharmacol. 2025, 16:1695177. 10.3389\/fphar.2025.1695177","journal-title":"Front Pharmacol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2016.06.007","article-title":"Clinical trials of aspirin treatment after desensitization in aspirin-exacerbated respiratory disease","volume":"36","author":"Kowalski ML","year":"2016","unstructured":"Kowalski ML, Wardzy\u0144ska A, Makowska JS. Clinical trials of aspirin treatment after desensitization in aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am. 2016, 36:705-17. 10.1016\/j.iac.2016.06.007","journal-title":"Immunol Allergy Clin North Am"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.5543\/tkda.2021.67827","article-title":"How to manage aspirin hypersensitivity in a patient with ST-segment elevation myocardial infarction and a drug-eluting stent","volume":"49","author":"\u00c7aml\u0131 E","year":"2021","unstructured":"\u00c7aml\u0131 E, Verdiyev H, Babayi\u011fit E, Kurt E, Ulus T. How to manage aspirin hypersensitivity in a patient with ST-segment elevation myocardial infarction and a drug-eluting stent. Turk Kardiyol Dern Ars. 2021, 49:167-70. 10.5543\/tkda.2021.67827","journal-title":"Turk Kardiyol Dern Ars"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.15586\/aei.v53i6.1457","article-title":"Drug-induced fixed urticaria because of hypersensitivity to non steroidal anti-inflammatory drugs","volume":"53","author":"G\u00f3mez-Aguado JJ","year":"2025","unstructured":"G\u00f3mez-Aguado JJ, Mu\u00f1oz AM, G\u00f3mez BC, Gil LM. Drug-induced fixed urticaria because of hypersensitivity to non steroidal anti-inflammatory drugs. Allergol Immunopathol (Madr). 2025, 53:157-61. 10.15586\/aei.v53i6.1457","journal-title":"Allergol Immunopathol (Madr)"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.farma.2010.09.008","article-title":"Toxic epidermal necrolysis with fatal ending due to the concurrent use of carbamazepine, cilostazol and omeprazol: a case report (Article in Spanish)","volume":"35","author":"Concepci\u00f3n Mart\u00edn I","year":"2011","unstructured":"Concepci\u00f3n Mart\u00edn I, Fern\u00e1ndez de Palencia Espinosa MA, Garrido Corro B, De La Rubia Nieto A. Toxic epidermal necrolysis with fatal ending due to the concurrent use of carbamazepine, cilostazol and omeprazol: a case report (Article in Spanish). Farm Hosp. 2011, 35:217-8. 10.1016\/j.farma.2010.09.008","journal-title":"Farm Hosp"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s40629-015-0048-2","article-title":"Hypersensitivity reactions to modern antiplatelet and anticoagulant drugs","volume":"24","author":"Hofmeier KS","year":"2015","unstructured":"Hofmeier KS. Hypersensitivity reactions to modern antiplatelet and anticoagulant drugs. Allergo J Int. 2015, 24:58-66. 10.1007\/s40629-015-0048-2","journal-title":"Allergo J Int"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.9213","article-title":"Hypersensitivity reaction to rivaroxaban with a successful switch to apixaban: a case report","volume":"12","author":"Mohammadi K","year":"2024","unstructured":"Mohammadi K, Ansari R, Yaribash S. Hypersensitivity reaction to rivaroxaban with a successful switch to apixaban: a case report. Clin Case Rep. 2024, 12:e9213. 10.1002\/ccr3.9213","journal-title":"Clin Case Rep"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15693","article-title":"Differences in the location of bleeding with direct oral anticoagulants vs. vitamin K antagonists: a study in the World Health Organization's pharmacovigilance database","volume":"89","author":"Montastruc JL","year":"2023","unstructured":"Montastruc JL, Tessier S, Bura-Riviere A. Differences in the location of bleeding with direct oral anticoagulants vs. vitamin K antagonists: a study in the World Health Organization's pharmacovigilance database. Br J Clin Pharmacol. 2023, 89:2201-7. 10.1111\/bcp.15693","journal-title":"Br J Clin Pharmacol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1177\/1060028017729481","article-title":"Influence of direct oral anticoagulants on anti-factor Xa measurements utilized for monitoring heparin","volume":"52","author":"Macedo KA","year":"2018","unstructured":"Macedo KA, Tatarian P, Eugenio KR. Influence of direct oral anticoagulants on anti-factor Xa measurements utilized for monitoring heparin. Ann Pharmacother. 2018, 52:154-9. 10.1177\/1060028017729481","journal-title":"Ann Pharmacother"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2011.01500.x","article-title":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms syndrome induced by cilostazol and carbamazepine","volume":"39","author":"Kang SY","year":"2012","unstructured":"Kang SY, Kim JY, Kim MY, et al.. Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms syndrome induced by cilostazol and carbamazepine. J Dermatol. 2012, 39:723-4. 10.1111\/j.1346-8138.2011.01500.x","journal-title":"J Dermatol"},{"key":"ref50","article-title":"Yakushinjoho: Collected Report of Drug Eruptions in Japan (21st Edition, 1980-2024)","author":"Fukuda H","year":"2025","unstructured":"Fukuda H. Yakushinjoho: Collected Report of Drug Eruptions in Japan (21st Edition, 1980-2024). Fukuda Dermatological Clinic, Japan; 2025."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/514692-antithrombotic-drug-eruptions-in-dermatology-practice-selection-bias-clinical-phenotypes-and-diagnostic-approaches","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T03:35:34Z","timestamp":1784172934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/514692-antithrombotic-drug-eruptions-in-dermatology-practice-selection-bias-clinical-phenotypes-and-diagnostic-approaches"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":50,"URL":"https:\/\/doi.org\/10.7759\/cureus.112751","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,15]]}}}